The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patients

Chinese Medicine

Per Hove Thomsen¹  Morten Frydenberg²  Shelagh Gwendolyn Powell¹ 

[1] Centre for Child and Adolescent Psychiatry, Aarhus University Hospital, Skovagervej 2, entr. 81, Risskov, 8240, Denmark;Department of Public Health, Aarhus University, Bartholins Allé, build. 1260, Aarhus C, 8000, Denmark

关键词: Long-term effects;    Growth;    ADHD;    Central stimulants;   

Others  :  1231848
DOI  :  10.1186/s13034-015-0082-3

 received in 2014-09-18, accepted in 2015-09-16,  发布年份 2015

【 摘 要 】

Background

Children and adolescents with ADHD treated with central stimulants (CS) often have growth deficits, but the implications of such treatment for final height and stature remain unclear.

Methods

Weight and height were assessed multiple times in 410 children and adolescents during long-term treatment with CS, which lasted between 0.9 and 16.1 years. Weight and height measures were converted to z-scores based on age- and sex-adjusted population tables.

Results

CS treatment was associated with (1) a relative reduction in body weight and a temporary halt in growth, (2) a weight and height lag after 72 months compared with relative baseline values. No relation to early start of medication (<6 years), gender, comorbid ODD/CD or emotional disorders was observed.

Conclusions

Treatment with central stimulants for ADHD impacts growth in children and adolescents, and growth should be continuously monitored in patients on chronic treatment with these medications.

【 授权许可】

   
2015 Powell et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

【 参考文献 】

• [1]Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A. European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry. 2004; 13:I7-I30.
• [2]Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008; 17:459-474.
• [3]Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry. 2006; 163:579-585.
• [4]Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff. 2007; 26:450-457.
• [5]Spencer TJ. ADHD treatment across the life cycle. J Clin Psychiatry. 2004; 65:22-26.
• [6]Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs. 2003; 5:787-794.
• [7]Gillberg C, Melander H, von Knorring AL, Janols L-O, Thernlund G, Hägglöf B, Eidevall-Wallin L, Gustafsson P, Kopp S. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized. Double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997; 54:857-864.
• [8]Halford JC, Blundell JE. Pharmacology of appetite suppression. Prog Drug Res. 2000; 54:25-58.
• [9]Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil. 2006; 27:162-174.
• [10]Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G. Randomized, controlled trial of oros methylphenidae once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108:883-892.
• [11]Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006; 45:1294-1302.
• [12]Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006; 45:1304-1313.
• [13]Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008; 47:994-1009.
• [14]Safer D, Allen R, Barr E. Depression on growth in hyperactive children on stimulant drugs. N Engl J Med. 1972; 287:217-220.
• [15]Safer DJ, Allen RP, Barr E. Growth rebound after termination of stimulant drugs. J Pediatr. 1975; 86:113-116.
• [16]Klein RG, Landa B, Mattes JA, Klein DF. Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry. 1988; 45:1127-1130.
• [17]Klein RG, Mannuzza S. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry. 1988; 45:1131-1134.
• [18]Satterfield JH, Cantwell DP, Schell A, Blaschke T. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry. 1979; 36:212-217.
• [19]Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health. 2003; 39:180-185.
• [20]Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab. 2003; 16:711-718.
• [21]Swanson J, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein J, Pelham WE, Abikoff HB, Newcorn JH, Molina BSG, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron M, Volkow ND. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007; 46:1015-1027.
• [22]Loney J, Whaley-Klahn MA, Ponto LB, Adney K. Predictors of adolescent height and weight in hyperkinetic boys treated with methylphenidate [proceedings]. Psychopharmacol Bull. 1981; 17:132-134.
• [23]Mattes JA, Gittelman R. Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry. 1983; 40:317-321.
• [24]Spencer TJ, Biederman J, Harding M, O’Donnell D, Faraone SV, Wilens TE. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996; 35:1460-1469.
• [25]Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B. Concerta Study Group. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006; 45:527-537.
• [26]Charach A, Ickowicz A, Schachar R. Stimulant treatment over 5 years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004; 43:559-567.
• [27]Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006; 45:520-526.
• [28]Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittman RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E. European Guidelines Group. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011; 20:17-37.
• [29]Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics. 1998; 102:501-506.
• [30]Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005; 90:801-806.
• [31]Greenhill LL, Puig-Antich J, Chambers W, Rubinstein B, Halpern F, Sachar EJ. Growth hormone, prolactin, and growth responses in hyperkinetic males treated with d-amphetamine. J Am Acad Child Adolesc Psychiatry. 1981; 20:84-103.
• [32]Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S. Predictors of adult height and weight in boys treated with methylhenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry. 2000; 39:517-524.
• [33]Biederman J, Faraone SV, Monuteaux MC, Plunkett EA, Gifford J, Spencer T. Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment. Pediatrics. 2003; 111:1010-1016.
• [34]Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010; 157:635-640.
• [35]Powell SG, Thomsen PH, Frydenberg M, Rasmussen H. Long-term treatment of ADHD with stimulants—a large observational study of real life patients. J Atten Disord. 2011; 15:439-451.
• [36]Weiss MD, Gadow KD, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006; 67:38-45.
• [37]Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, Schopler E. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord. 1989; 19:185-212.
• [38]Wikland KA, Luo ZC, Niklasson A, Karlberg J. Swedisk population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. Acta Paediatr. 2002; 91:739-754.
• [39]Birkebaek NH, Kamperis K, Main KM, Johannesen J, Naerå RW. Hertel NT [Recommendation for identical growth curves in Denmark]. Ugeskr Laeger. 2007; 169:1669-1671.
• [40]Stata 12. College Station, Texas StataCorp. 2011. http://www. stata.com/ webcite
• [41]SAS 9.2. Cary, NC: SAS Institute Inc. 2008. http://www. sas.com/en_us/software/analytics/stat.html webcite
• [42]Waring ME, Lapane KL. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. Pediatrics. 2008; 122:e1-e6.
• [43]Malone RP, Waheed A. The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism. Drugs. 2009; 69:535-548.